BDR Pharmaceutical launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers today. BDPARIB is the first

Drug major on Thursday said it has received payment of USD 50 million (around Rs 363.5 crore)

Novartis announced robust data from the primary analysis of the pivotal phase II ELARA trial of Kymriah

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator

The FDA’s crackdown on drugs that aren’t meeting approval requirements has now hit Roche. The Swiss pharmaceutical

Alkem Laboratories Limited has agreed to partner with Tata Memorial Centre (TMC) to establish an advanced Radiotherapy